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Abstract
Background: We determined the impact of three factors on mortality in HIV-infected patients who had been on highly
active antiretroviral therapy (HAART) for at least one year: (1) insufficient response to (HAART) and presence of AIDS-
defining diseases, (2) comorbidity, and (3) drug and alcohol abuse and compared the mortality to that of the general
population.
Methodology/Principal Findings: In a Danish nationwide, population-based cohort study, we used population based
registries to identify (1) all Danish HIV-infected patients who started HAART in the period 1 January 1998–1 July 2009, and
(2) a comparison cohort of individuals matched on date of birth and gender (N=2,267 and 9,068, respectively). Study
inclusion began 1 year after start of HAART. Patients were categorised hierarchically in four groups according to the three
risk factors, which were identified before study inclusion. The main outcome measure was probability of survival from age
25 to 65 years. The probability of survival from age 25 to age 65 was substantially lower in HIV patients [0.48 (95%
confidence interval (CI) 0.42–0.55)] compared to the comparison cohort [0.88 (0.86 to 0.90)]. However, in HIV patients with
no risk factors (N=871) the probability of survival was equivalent to that of the general population [0.86 (95% CI 0.77–0.92)].
In contrast, the probability of survival was 0.58 in patients with HIV risk factors (N=704), 0.30 in patients with comorbidities
(N=479), and 0.03 in patients with drug or alcohol abuse (N=313).
Conclusions: The increased risk of death in HIV-infected individuals is mainly attributable to risk factors that can be
identified prior to or in the initial period of antiretroviral treatment. Mortality in patients without risk factors on a successful
HAART is almost identical to that of the non–HIV-infected population.
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Introduction
Since the introduction of highly active antiretroviral therapy
(HAART), the risk of death has decreased substantially in the
HIV-infected population, but remains markedly higher than in the
general population [1]. Several explanations have been proposed,
including the detrimental impact of non-HAART-related lifestyle
factors such as smoking and drug abuse, presence of other diseases,
exposure to co-pathogens (e.g., hepatitis C), side effects of HAART
(e.g., myocardial infarction), presence of HIV-related diseases, and
failure to obtain full immune reconstitution [2–6].
Recently it has been proposed that, despite successful treatment,
HIV-infected patients suffer from accelerated aging driven by
residual immune activation [7]. Limitations of previous research
on risk of death among HIV-infected individuals include non-
population based designs, lack of access to information on major
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22698pre-HIV-infection and post-HAART risk factors, as well as lack of
information on risk factors in general population comparison
cohorts [8]. Three groups of risk factors consistently have been
reported to increase mortality among the HIV-infected patients on
HAART: (1) HIV-related risk factors (AIDS defining diseases and
insufficient response to HAART), (2) comorbidities including
hepatitis C, and (3) drug and alcohol abuse.
We used a Danish population-based cohort of HIV-infected
patients and a comparison cohort from the general population to
(1) estimate the impact of risk factors identifiable in the initial
period of antiretroviral therapy on long-term mortality in the
HIV-infected population and (2) determine the relative risk of
death, compared to the background population, among success-
fully treated HIV-infected patients without such risk factors.
Methods
Ethics
Since the study is entirely based on data from national registries
and clinical databases, there was according to Danish law no
request for an ethical permission (Denmark has no Institutional
review boards). The study was approved by Danish Data
Protection Agency.
Setting
Among Denmark’s population of 5.4 million, the estimated
prevalence of HIV-infection in adults is 0.09%. Denmark’s tax-
funded health care system provides antiretroviral treatment free-
of-charge to all HIV-positive residents. During the study period,
national guidelines stipulated one or more of the following criteria
for initiating HAART in HIV-positive individuals: presence of an
HIV-related disease, acute HIV-infection, pregnancy, CD4 cell
count ,300 cells/ml, and, until 2001, plasma HIV-RNA.100,000
copies/ml. Patients are seen on an outpatient basis at intended
intervals of 12 weeks.
Data Sources
We used the unique 10-digit Central Person Registration (CPR)
number assigned to all Danish citizens at birth or immigration, to
avoid multiple registrations and to track individuals in national
healthcare registries. HIV-infected patients were identified from
the Danish HIV Cohort Study, which includes all HIV-infected
patients treated in Denmark’s eight specialized HIV centers since
January 1, 1995 [9]. The Danish Civil Registration System (CRS),
a national registry containing information on the vital status of all
citizens and other demographic data [10] allowed us to identify a
population-based comparison cohort and to extract data on birth,
gender, date of immigration and emigration, loss to follow-up, date
of death, and place of birth, both for the HIV-infected patients
and the comparison cohort. Data on comorbidity, alcohol abuse,
and drug abuse were extracted from the Danish National Registry
of Patients, which contains information on all patients discharged
from Danish non-psychiatric hospitals [11]. Records for each
inpatient admission include dates of admission and discharge and
diagnoses, coded by the attending physician according to the
International Classification of Diseases.
Study populations
We included HIV-infected patients aged 25–65 who started
HAART between 1 January 1998 and 1 July 2009, were registered
in the CRS, and lived in Denmark at start of HAART. HAART
was defined as a treatment regimen of at least three antiretroviral
drugs or a treatment regimen including a combination of a non-
nucleoside reverse transcriptase inhibitor and a boosted protease
inhibitor. For HIV-infected patients, the index date was defined as
1 year after start of HAART.
We also used the CRS to identify a comparison cohort drawn
from the general population, consisting of 4 individuals for each
HIV-infected patient, matched on age and date of birth. To be
eligible, matched individuals had to be alive on the index date of
the corresponding HIV-infected patient, had to be living in
Denmark on the date the corresponding patient started HAART,
and could not be registered as having a comorbidity included in
the Charlson Comorbidity Index (CCI), alcoholism, or drug abuse,
as of the index date. The index date of individuals in the
comparison cohort was defined as the index date of the
corresponding HIV-infected patient.
Risk factors
Risk factors were defined as follows:
HIV risk factors. Detectable viral load (.49 copies/ml)
and/or CD4 below 200 cells/ul at the last measurement prior to
the index date and/or AIDS- defining disease as of the index date.
Comorbidity. Diagnosed with comorbidity (excluding AIDS-
defining diseases) as defined in the Charlson comorbidity index
(CCI) [12–14] before the index date. Hepatitis C, if registered in
the Danish HIV Cohort Study, also was included as comorbidity.
Alcohol and drug abuse. Drug abuse reported as the route
of HIV transmission or hospital contacts before the index date
with the following diagnoses: ICD-8: 29100–29199, 57109, 57110,
30300–30389, 30391–30399, 30409–30499; and ICD-10: K700–
K709, F102–109, G312, F110–199, or T400.
Statistical analysis
For HIV-infected patients and the comparison cohort, we
calculated person-years (PY) of follow-up from the index date to
age 65, emigration, date of death, or 1 July 2010, whichever came
first. The study outcome was time to death from any cause.
Study participants were categorized into the following risk
groups:
Group 0 (General population comparison cohort): HIV risk
factors: 2, comorbidity: 2, abuse: 2.
Group 1 (HIV-infected patients): HIV risk factors: 2,
comorbidity: 2, abuse: 2.
Group 2 (HIV-infected patients): HIV risk factors: +, comor-
bidity: 2, abuse: 2.
Group 3 (HIV-infected patients): HIV risk factors: +/2,
comorbidity: +, abuse: 2.
Group 4 (HIV-infected patients): HIV risk factors: +/2,
comorbidity: +/2, abuse: +..
We computed Kaplan-Meier tables using age as the time
variable and stratifying on the above 5 risk groups. We calculated
mortality rate ratios (MMRs) and corresponding 95% confidence
intervals for each risk group, stratified into two age categories (25–
,45 years and 45–65 years) [15]. In stratified analyses, only
individuals in the population comparison cohort who were
matched to the respective HIV patients were included in the
calculations.
SPSS version 15.0 (SPSS Inc., Chicago, Il, USA) and Stata
version 8.0 (Stata Corporation, College Station, Texas, USA) were
used to perform the analyses.
Results
We identified 871 individuals in Group 1, 704 in Group 2, 379 in
Group 3, 313 in Group 4, and 9,068 in the general population
comparison cohort (Group 0), which in stratified analyses were
divided in 4 comparison cohorts (for Group 1, 3484 individuals,
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individuals). Due to the inclusion criteria, no individuals in the
general population comparison cohort were diagnosed with
comorbidity or drug or alcohol abuse as of the index date
(Table 1). The major comorbidity in the Charlson index was
attributable to liver diseases (table 1). More HIV-infected patients
were born outside Denmark than persons in the comparison cohort.
Other characteristics of the study cohorts are described in Table 1.
The HIV population suffered from substantially increased
mortality [MRR=8.58 (95% confidence interval 5.79 to 12.71)
among patients aged 25–45 and MRR=6.00 (4.65 to 7.77)]
among those aged 45–65). However, in Group 1 (HIV-infected
patients without HIV risk factors, comorbidity, or alcohol/drug
abuse) mortality was almost equal to that of the general population
comparison cohort for the age group 45–65 [MRR=1.14 (0.58 to
2.23)], but doubled for the age group 25–45 [MRR=2.02 (0.61 to
6.70)] (Table 2).
The relative risk of death increased by risk group (Table 2),
ranging from a fourfold increased risk of death in HIV patients
aged 45–65 years with HIV risk factors, but no comorbidity or
Table 1. Characteristics of the study population.
General
population
comparison
cohort
(Group 0)
HIV-infected
patients with
no risk factors
(Group 1)
HIV-infected
patients with
HIV risk factors
(Group 2)
HIV-infected
patients with
comorbidity
(Group 3)
HIV-infected
patients with
alcohol/drug
abuse
(Group 4)
Number of patients 9,068 871 704 379 313
Median years of follow up, years 5.91 5.15 6.35 4.60 5.01
Person-years of follow up (years) 53,015 4,614 4,296 1,858 1,599
Median age at study entry, years (IQR*) 40 (35–47) 40 (34–46) 39 (34–46) 44 (38–53) 40 (36–46)
Males (n, %) 6,704 (73.9%) 659 (75.7%) 493 (70.0%) 318 (83.9%) 206 (65.8%)
Deceased during follow-up (n, %) 138 (1.5%) 15 (1.7%) 51 (7.2%) 58 (15.0%) 89 (28.4%)
Emigrated during follow-up (n, %) 91 (1.0%) 16 (1.80%) 21 (4.0%) 7 (1.8%) 1 (0.6%)
Lost to follow up (n, %) 2 (0.0%) 3 (0.3%) 2 (0.3%) 2 (0.5%) 1 (0.3%)
Born outside Denmark (n, %) 677 (7.5%) 253 (29.0%) 276 (39.2%) 90 (23.7%) 45 (14.4%)
Comorbidity (n, %)** 0 (0%) 0 (0%) 0 (0%) 379 (100.0%) 262 (83.7%)
Neurologic disease (n, %) 0 (0%) 0 (0%) 0 (0%) 50 (13.2%) 10 (3.27%)
Cardiovascular disease (n, %) 0 (0%) 0 (0%) 0 (0%) 30 (7.9%) 16 (5.1%)
Pulmonay disese(n, %) 0 (%) 0 (0%) 0 (0%) 56 (14.8%) 27 (8.6%)
Gastroentorologic disease (n, %) 0 (%) 0 (0%) 0 (0%) 42 (11.1%) 18 (5.8%)
Liver disease (n, %) 0 (%) 0 (0%) 0 (0%) 148 (39.1%) 251 (80.2%)
Renal disease (n, %) 0 (%) 0 (0%) 0 (0%) 17 (3.9%) 3 (1.0%)
Diabetes (n, %) 0 (%) 0 (0%) 0 (0%) 22 (5.8%) 4 (1.3%)
Rheumatological disease (n, %) 0 (%) 0 (0%) 0 (0%) 17 (4.5%) 1 (0.3%)
Malignant disease (n, %) 0 (%) 0 (0%) 0 (0%) 62 (16.4%) 10 (3.2%)
Abuse (n, %) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 323 (100.0%)
Drug abuse(n, %) 0 (%) 0 (0%) 0 (0%) 0 (0%) 266 (85.0%)
Alcohol abuse (n, %) 0 (%) 0 (0%) 0 (0%) 0 (0%) 93 (29.7%)
Hepatitis C (n, %) 0 (%) 0 (0%) 0 (0%) 107 (28.2%) 240 (76.7%)
Infection mode:
Homosexual contact (n, %) 454 (52.1%) 303 (43.0%) 194 (51.2%) 24 (7.7%)
Heterosexual contact (n, %) 379 (43.5%) 368 (52.3%) 147 (38.8%) 21 (6.7%)
Injection drug use (n, %) 0 (0%) 0 (0%) 0 (0%) 266 (85.0%)
Other/unknown (n, %) 38 (4.3%) 33 (4.7%) 38 (10.0%) 2 (0.6%)
Caucasians (n, %) 675 (77.5%) 474 (67.3%) 319 (84.2%) 289 (92.3%)
Diagnosed with HIV before 1 January 1995 (n, %) 132 (15.5%) 122 (17.3%) 89 (23.4%) 115 (36.7%)
Diagnosed with AIDS before start of HAART (n, %) 0 (0%) 311 (44.2%) 105 (27.7%) 58 (18.5%)
Viral load detectable 1 year after start of HAART (n, %) 0 (0%) 332 (47.2) 81 (21.4%) 105 (32.9%)
CD4 at diagnosis (median, IQR) 360 (240–513) 150 (50–370) 300 (120–504) 368 (230–550)
CD4 below 200 cells/ul 1 year after index date (n, %) 0 (0%) 297 (42.2%) 80 (21.1%) 63 (20.1%)
Started HAART after 1 January 2005 (n, %) 202 (23.2%) 153 (21.7%) 89 (23.5%) 45 (14.4%)
*IQR=interquartile range.
**: As patients could have more than one type of comorbidity, the sum of comorbidities is higher than the number of patients with comorbitiy.
doi:10.1371/journal.pone.0022698.t001
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in HIV patients registered with alcohol or drug abuse. The
probability of survival at 65 years of age was 0.48 among HIV-
infected patients and 0.88 in the general population comparison
cohort. However, for HIV patients with no risk factors, the
probability of survival at age 65 was 0.86 (Figure 1). The
probability of survival declined to 0.58 in Group 2 (patients with
HIV risk factors), to 0.30 in Group 3 (HIV-infected patients with
comorbidity), and to 0.03 in Group 4 (those with alcohol or drug
abuse).
Discussion
Our study confirms that HIV-infected patients on HAART
suffer from a substantially increased risk of death compared to the
general population. However, mortality was associated mainly
with well-known HIV- and non-HIV-associated risk factors, which
are identifiable prior to or in the initial phase of HAART
treatment. Mortality in HIV-infected patients with no identifiable
risk factors was almost identical to that of the general population
with no risk factors. Importantly, increased risk of death was
observed only in patients registered with one or more risk factors
in the initial phase of HAART treatment.
The major strength of the study is its nationwide population-
based design combined with long and nearly complete follow-up.
Furthermore, access to comprehensive Danish medical and
demographic databases permitted us to identify a well-matched
population-based comparison cohort and allowed us to estimate
the impact of major risk factors.
The study has several potential limitations. We could not
account for smoking as we lacked information on tobacco use in
the population comparison cohort. We relied on registry-based
hospital diagnoses to identify comorbidities and alcohol/drug
abuse and we had access to alcohol/drug abuse data for the
comparison population only if it led to contact with the health care
system. However, we assume that these factors cannot explain our
results, as smoking and drug abuse is likely to be more prevalent
among HIV-infected patients [16]. The risk-taking behavior
leading to HIV acquisition also may have led to other exposures
with long latency periods, not manifested at the index date.
However, our findings do not indicate that such risk-taking
behavior led to increased mortality in appropriately treated HIV-
infected patients without other risk factors. More HIV patients
were born outside Denmark which may give rise to some healthy
survivor effects.
We included only the age group from 25–64 years, as the
number of patients outside this range was too low to allow
conclusions to be drawn. Therefore, our findings cannot be
extended beyond this age interval. Few deaths were observed in
the age group 25–45 years in the comparison cohort and in the
HIV patients without risk factors why the estimates of risk of death
in these categories are imprecise. Therefore we cannot rule out an
increased risk of death in this age interval. In more than 60% of
the HIV patients, one or more risk factors were identifiable why a
substantial excess mortality is to be expected in the general HIV
population.
It has been proposed that HIV is associated with premature
aging, driven by residual inflammation, even with fully suppressed
viral load. Although premature aging is not a well defined entity, it
is thought to be associated with increased risk of death. As we did
not observe substantially increased mortality among HIV patients
without risk factors, our data does not support the theory of
premature aging. Rather, the data establish that the increased risk
of death in the HIV population on HAART mainly stems from
classic risk factors.
Previous large-scale cohort studies comparing mortality in HIV-
infected patients with that in the general population have found
increased mortality in the HIV-infected group [1,8,17,18].
However, several reports identified subsets of HIV-infected
patients with no increased mortality compared with the general
population (generally sexually infected patients on HAART with a
CD4 cell count above 500 cells/mm
3) [8,17,19]. In these reports
the general population, in which a substantial amount of
comorbidity and drug or alcohol abuse is present, was used as
Table 2. Mortality and mortality rate ratios by risk group.
Groups
Probability of
survival from
age 25 to 65
years 95% CI
Age
interval Deaths PY** MR***
95% confidence
interval MRR****
95% confidence
interval
Comparison cohort 0.88 0.86 0.90 25–45 37 29123 1.27 0.92 1.75
45–65 101 23899 4.23 3.48 5.14
HIV overall 0.48 0.42 0.53 25–45 76 6973 10.90 8.70 13.64 8.58 5.79 12.71
45–65 137 5395 25.39 21.47 30.02 6.00 4.65 7.77
Group 1* 0.86 0.77 0.92 25–45 4 2723 1.47 0.55 3.91 2.02 0.61 6.70
45–65 11 1891 5.82 3.22 10.50 1.14 0.58 2.23
Group 2* 0.58 0.48 0.67 25–45 21 2525 8.32 5.42 12.76 4.62 2.48 8.60
45–65 30 1772 16.93 11.84 24.21 4.27 2.57 7.08
Group 3* 0.30 0.21 0.40 25–45 15 826 18.15 10.94 30.11 12.75 4.64 35.09
45–65 43 1032 41.68 30.91 56.20 10.79 6.29 18.52
Group 4* 0.03 0.003 0.12 25–45 36 898 40.07 28.90 55.55 32.60 12.79 83.08
45–65 53 701 75.66 57.80 99.03 21.90 11.94 40.17
*For definition of Groups 1–4, see Figure 1.
**PY=person-years.
***MR=mortality rate (deaths/1000 PY).
****MRR=mortality rate ratio.
doi:10.1371/journal.pone.0022698.t002
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mortality may have been due to confounding introduced by
comorbidity, alcohol abuse and injection drug use in the general
population. Because we used a comparison cohort from the
general population restricted to persons with no comorbidity,
alcohol or drug abuse, these confounders were eliminated from
our study [20]. Our findings thus improve the level of evidence
that HIV-infection, when treated optimally, does not increase the
risk of death substantially.
Recently, comorbidity has been identified as the major risk factor
for death among HIV-infected patients not yet on HAART [19].
We supplement this finding by demonstrating that comorbidity, as
well as HIV risk factors and alcohol/drug abuse, are also major risk
factors for death in HIV-infected patients on HAART.
We conclude that HIV-infected patients on HAART still suffer
from substantial excess mortality, but the increased risk of death
stems mainly from HIV- and non-HIV related risk factors, which
can be identified prior to or in the initial phase of HAART
treatment. Future management of the HIV-infected population
should focus on early diagnosis, timely and effective HAART, and
treatment of comorbidity and alcohol/drug abuse. Serious
attention should be given to non-HIV related conditions among
HIV-infected persons. However, stressing the impact of HIV on
mortality after HAART initiation may severely hamper the
patients’ quality of life and be at odds with present data.
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Figure 1. Cumulative survival for HIV-infected patients starting HAART and persons from the general population. Time was calculated
from 1 year after start of HAART. The study population was categorized as: Group 0: Population comparison cohort (dotted line, N=9,068). Group 1:
HIV-infected patients without HIV risk factors, comorbidity or alcohol/drug abuse (N=871). Group 2: HIV-infected patients with HIV risk factors, but
no comorbidity or alcohol/drug abuse (N=704). Group 3: HIV-infected patients with comorbidity, but no alcohol/drug abuse (N=379). Group 4: HIV-
infected patients with alcohol/drug abuse (N=313). HIV risk factors: detectable viral load (.49 copies/ml) and/or CD4 below 200 cells/ul at the last
measurement prior to the index date and/or AIDS- defining disease as of the index date. Comorbidity: diagnosed with comorbidity as defined in the
Charlson Comorbidity Index before index date. Abuse: diagnosed with drug or alcohol abuse before index date or reporting drug abuse as route of
HIV transmission.
doi:10.1371/journal.pone.0022698.g001
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